GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

28:41 | Mar 18th, 2016

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.